We are thrilled to share some exciting news with you: Corify Care has achieved CE Mark certification under the Medical Device Regulation (MDR) for our groundbreaking ACORYS MAPPING SYSTEM! This certification is a testament to our unwavering commitment to safety, health, and environmental protection standards for medical devices in the European Union, and it has only been possible thanks to the incredible work and dedication of our entire team.
What is the ACORYS MAPPING SYSTEM?
The ACORYS MAPPING SYSTEM is the fastest non-invasive cardiac mapping technology on the market. It visualizes the heart’s electrical activity in under 10 minutes, eliminating the need for CT or MRI scans. By utilizing body surface potential measurements and a 3D torso model, ACORYS generates highly detailed electroanatomical maps of the heart. This advanced system enhances the diagnosis and treatment of cardiac arrhythmias with unparalleled precision, speed, and safety.
Impact of CE Mark Certification
With the CE Mark, the ACORYS MAPPING SYSTEM is now approved for commercial sale throughout the European Union. Hospitals and cardiac care centers can now utilize this cutting-edge technology to provide patients with precise and rapid cardiac mapping. This will significantly improve the diagnosis and treatment of various arrhythmias, including atrial fibrillation and ventricular tachycardia.
Benefits of the ACORYS MAPPING SYSTEM
The ACORYS MAPPING SYSTEM offers numerous benefits, making it a game-changer in the field of cardiac care:
- Speed and Precision: Our system produces real-time, detailed heart maps, facilitating quick and accurate clinical decisions.
- Non-Invasive: It can be used when invasive mapping is not available (e.g., cardiac resynchronization therapy, regular consultations), or combined with invasive mapping for enhanced procedures.
- Comprehensive Analysis: ACORYS allows continuous monitoring and detailed analysis, generating new maps with each heartbeat.
Future Prospects
With the CE Mark, we are set to expand our market presence across Europe and aim to integrate the ACORYS MAPPING SYSTEM into clinical practice worldwide. Our next steps include obtaining FDA approval in the United States and expanding to other international markets. We are committed to continuous innovation and have plans to develop ACORYS 2.0, incorporating digital twins and new clinical applications. We are incredibly proud of this milestone and look forward to revolutionizing cardiac care with the ACORYS MAPPING SYSTEM. Thank you for your continued support as we embark on this exciting journey to improve heart health around the world.
